[Form 4] iTeos Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Michel Detheux, reporting as Chief Executive Officer and Director of iTeos Therapeutics, Inc. (ITOS), reported transactions dated 08/29/2025 tied to a completed merger with Concentra Biosciences LLC. At the merger's Effective Time each outstanding share was converted into $10.047 cash per share plus one non-transferable contractual contingent value right (CVR). The filing shows the reporting person and MG3A disposed of all reported common stock and restricted stock units and certain stock options were canceled in exchange for cash (for in-the-money options) and CVRs. Following the transactions, reported beneficial ownership of the listed securities is zero for the reported holdings.

Positive

• Cash consideration of $10.047 per share provided liquidity to holders
• Non-transferable CVRs issued preserve contingent upside tied to post-close milestones
• Accelerated vesting and cash settlement ensured immediate payment for restricted stock units and vested options

Negative

• Reported holdings reduced to zero for listed common stock and options following the Merger
• In-the-money options canceled and converted to cash rather than retaining equity exposure

Insights

Financial Analyst

TL;DR: The Form 4 records a cash-and-CVR merger exit for the CEO, converting all reported equity into $10.047 per share plus contingent rights.

The filing documents a change-in-control settlement where outstanding common shares, restricted stock units and in-the-money options were converted or canceled at the Effective Time. In-the-money options were cashed out based on the excess of the $10.047 cash amount over exercise prices. The transactions remove the reported equity positions and realize value for the holder; this is a material corporate liquidity event arising from the Merger Agreement.

Corporate Governance Expert

TL;DR: Accelerated vesting and cash-outs were applied per the Merger Agreement, producing immediate settlement of equity awards for covered service providers.

The Committee executed terms providing for automatic vesting and cancellation where applicable, with replacement consideration of cash and CVRs. The filing also discloses indirect holdings via MG3A and manager relationships, clarifying beneficial ownership structure. The disclosure aligns with Section 16 reporting for change-in-control transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Detheux Michel

(Last) (First) (Middle)

C/O ITEOS THERAPEUTICS, INC.

321 ARSENAL STREET

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iTeos Therapeutics, Inc. [ ITOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		U(1)(2)(3)		153,903	D	(1)(2)(3)	0	D
Common Stock	08/29/2025		U(1)		94,027	D	(1)	0	I	By MG3A(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.05	08/29/2025		D(5)			14,185	(5)(6)	(5)(6)	Common Stock	14,185	(5)(6)	0	D
Stock Option (Right to Buy)	$7.05	08/29/2025		D(5)			444,815	(5)(6)	(5)(6)	Common Stock	444,815	(5)(6)	0	D
Stock Option (Right to Buy)	$4.24	08/29/2025		D(6)			94,336	(6)	(6)	Common Stock	94,336	(6)	0	D
Stock Option (Right to Buy)	$4.24	08/29/2025		D(6)			50,128	(6)	(6)	Common Stock	50,128	(6)	0	D
Stock Option (Right to Buy)	$6.16	08/29/2025		D(6)			17,544	(6)	(6)	Common Stock	17,544	(6)	0	D
Stock Option (Right to Buy)	$4.24	08/29/2025		D(6)			185,000	(6)	(6)	Common Stock	185,000	(6)	0	I	By MG3A(4)
Stock Option (Right to Buy)	$6.16	08/29/2025		D(6)			52,700	(6)	(6)	Common Stock	52,700	(6)	0	I	By MG3A(4)

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the "Cash Amount"); plus (ii) one non-transferable contractual contingent value right per share (each, a "CVR"), without interest and subject to applicable withholding of taxes.

2. The amount reported in Column 4 includes 108,875 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company (the "Committee") and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or

3. (Continued from footnote 2) within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit") that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the Cash Amount and (y) one CVR.

4. MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.

5. Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full.

6. In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.

	/s/ Adi Osovsky, as Attorney-in-Fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michel Detheux report on Form 4 for ITOS?

The Form 4 reports that Michel Detheux disposed of reported common stock and equity awards on 08/29/2025 in connection with the Merger, converting holdings to $10.047 cash per share plus one CVR per share.

How much cash was paid per iTeos share in the merger?

The filing states each issued and outstanding share was converted into $10.047 in cash per share plus one CVR.

Were options and restricted stock units affected by the merger?

Yes. Restricted stock units and certain stock options accelerated vesting and/or were canceled; in-the-money options were cashed out for the excess of $10.047 over the exercise price and also received CVRs.

Does the filing disclose any indirect ownership?

Yes. Some holdings were reported as indirectly owned by MG3A, a Belgian partnership for which the reporting person is manager and the spouse is successor manager.

What is a CVR as described in this filing?

The filing describes a CVR as a non-transferable contractual contingent value right issued per share at the Effective Time; the document does not provide further details on CVR terms.